PubMed Health⌕ Search

PubMed · 8987074

In-vitro dissolution profile comparison: statistics and analysis, model dependent approach.

Abstract

PURPOSE: To develop and propose a "model dependent' approach for the in-vitro dissolution profiles comparison. METHODS: Diltiazem hydrochloride tablet dissolution profiles were compared using a statistical approach based on a mathematical model. A similarity region (SR) was defined based on the intra- and inter-lot parameter variances of the final production size standard lots. Statistical distances between the test and reference lot parameter means were computed and normalized. A 90% confidence region (CR) was developed around the statistical distance. The confidence region was compared with the similarity region to assess the similarity or dis-similarity of the test and reference (REF) lot dissolution profiles. Two test lots, one with a "minor' modification (mm) the other with a "major' modification (MM), were evaluated. RESULTS: "Weibull' was selected as the "model' function. A comparison of the confidence regions around the statistical distance of "mm-REF' and "MM-REF' with the similarity region, suggested that the dissolution profiles of the "minor' modification lot were similar and that of "major' modification lot were dis-similar to the reference lot. CONCLUSIONS: A "model dependent' approach was shown to be useful for the inter-lot in-vitro dissolution profiles comparison.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P M Sathe, Y Tsong, V P Shah. 1996. In-vitro dissolution profile comparison: statistics and analysis, model dependent approach.. https://doi.org/10.1023/a%3A1016020822093

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Cardiovascular therapy and pharmacogenetics in 2007.

John Carlquist received a PhD from the Department of Cellular Viral and Molecular Biology at the University of Utah School of Medicine (UT, USA) with research emphasis in molecular immunology. After completion of his training, he received a faculty appointment in the Department of Internal Medicine, University of Utah, where he became interested in immune mechanisms in cardiovascular disease. He developed an interest in genetics through studies of human leukocyte antigen (HLA) associations with idiopathic dilated cardiomyopathy and rheumatic heart disease. He began the Molecular Diagnostics Laboratory for Intermountain Healthcare and continues to serve as Technical Director; he also directs the Intermountain Heart Study Molecular and Genetic Research Laboratory. Current research interests include the genetics of lipid metabolism as related to coronary heart disease and the genetic factors influencing drug treatment outcomes.

Cardiovascular Agents↗

Ensuring that patients receive full cardiac pharmacotherapy services: a pharmacist's call to arms.

While clinical trials have proven that use of certain cardiovascular drugs improves morbidity and mortality, these drugs are not widely used, they are by and large prescribed in suboptimal doses, and their benefit is further diminished by nonadherence. Pharmacists have the ability to improve the survival of patients with cardiovascular risks. This can only be accomplished through the efforts of the individual pharmacist and the further development of health-system management services. Pharmacists need to leverage their access to patients, their large patient base, and their knowledge of refill dates to improve patient care. Support and development of more pharmacist-directed anticoagulation, hyperlipidemia, and hypertension clinics are also needed.

Cardiovascular Agents↗